CLLS
Cellectis S.A. NASDAQ Listed Mar 24, 2015$2.92
+3.55%
vs $2.82
Mkt Cap $293.2M
52w Low $1.40
37.3% of range
52w High $5.48
50d MA $3.65
200d MA $3.81
P/E (TTM)
—
EV/EBITDA
—
P/B
3.9x
Debt/Equity
1.6x
ROE
—
P/FCF
-6.7x
RSI (14)
26.10
ATR (14)
$0.16
Beta
2.71
50d MA
$3.65
200d MA
$3.81
Avg Volume
46.3K
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
8, rue de la Croix Jarry · Paris 75013 · FR
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | AMC | -0.20 | -0.26 | -27.9% | 3.48 | -3.2% | -4.0% | +2.4% | -5.6% | +4.3% | -5.3% | — |
| Nov 7, 2025 | AMC | -0.10 | 0.01 | +110.0% | 3.19 | +12.5% | +11.3% | +4.8% | -1.9% | -2.2% | +9.2% | — |
| Aug 4, 2025 | AMC | -0.10 | -0.24 | -140.0% | 3.02 | +2.0% | -16.2% | +7.1% | -1.8% | -2.3% | +1.9% | — |
| May 12, 2025 | AMC | -0.19 | -0.18 | +5.3% | 1.51 | -6.0% | -6.6% | -2.1% | +5.8% | +8.2% | -1.9% | — |
| Mar 13, 2025 | AMC | 0.06 | -0.16 | -366.7% | 1.29 | +8.5% | -3.9% | -0.8% | +3.3% | +3.1% | -3.1% | — |
| Nov 4, 2024 | AMC | -0.20 | -0.23 | -15.0% | 1.76 | +8.0% | +1.1% | -0.6% | -1.1% | +1.1% | +7.9% | — |
| Aug 6, 2024 | AMC | -0.33 | -0.28 | +15.2% | 2.07 | -1.0% | -0.5% | +0.5% | +0.5% | -1.9% | +1.0% | — |
| Apr 29, 2024 | AMC | -0.33 | -0.64 | -93.9% | 2.56 | -1.6% | +0.0% | -0.8% | +17.7% | +0.0% | +12.0% | — |
| Mar 13, 2024 | AMC | -0.22 | -0.70 | -218.2% | 2.56 | +3.1% | -1.2% | +0.4% | -2.0% | -3.2% | +1.7% | — |
| Nov 6, 2023 | AMC | -0.36 | -0.31 | +13.9% | 2.76 | +0.7% | -13.4% | +4.6% | -4.0% | +4.6% | +0.4% | — |
| Aug 3, 2023 | AMC | -0.38 | -0.14 | +63.2% | 1.95 | +0.5% | -5.1% | +0.0% | +0.0% | -1.1% | +2.7% | — |
| May 4, 2023 | AMC | -0.30 | -0.58 | -93.3% | 1.88 | +0.5% | +1.1% | +0.0% | -3.7% | +4.9% | -5.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 28 | Barclays | Initiates | Overweight | $9 | $3.63 | $3.73 | +2.8% | +0.0% | -3.0% | -1.1% | -2.9% | -8.6% |
| Apr 14 | Citizens | Maintains | Market Outperform → Market Outperform | — | $4.28 | $4.23 | -1.2% | -2.8% | -1.7% | +4.4% | +3.5% | -7.2% |
| Oct 17 | Barclays | Maintains | Overweight → Overweight | — | $4.52 | $4.40 | -2.7% | -11.9% | -0.8% | -6.8% | -2.4% | -3.3% |
| May 13 | Barclays | Maintains | Overweight → Overweight | — | $1.51 | $1.42 | -6.0% | -6.6% | -2.1% | +5.8% | +8.2% | -1.9% |
| Nov 5 | Barclays | Maintains | Overweight → Overweight | — | $1.76 | $1.90 | +8.0% | +1.1% | -0.6% | -1.1% | +1.1% | +7.9% |
| Jun 12 | Oppenheimer | Maintains | Outperform → Outperform | — | $2.48 | $2.48 | +0.0% | -2.4% | -2.5% | -4.7% | -4.9% | -5.6% |
| May 31 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $2.71 | $2.71 | +0.0% | +0.0% | -2.2% | -3.0% | +6.2% | -2.2% |
| Nov 1 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $0.97 | $2.71 | +179.4% | +172.2% | +14.0% | -5.0% | -3.5% | -13.4% |
| Aug 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $1.85 | $1.84 | -0.5% | +0.0% | -1.1% | +2.7% | +3.2% | -0.5% |
| Aug 7 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $1.85 | $1.89 | +2.2% | +0.0% | +0.0% | -1.1% | +2.7% | +3.2% |
| Apr 5 | Citigroup | Maintains | Buy → Buy | — | $1.97 | $1.92 | -2.5% | +0.5% | -0.5% | -0.5% | +1.0% | +3.5% |
| Mar 13 | JMP Securities | Maintains | Market Outperform → Outperform | — | $1.99 | $1.96 | -1.5% | -1.5% | +1.0% | -7.6% | +1.6% | +1.1% |
| Mar 13 | Oppenheimer | Maintains | Outperform → Outperform | — | $1.99 | $1.96 | -1.5% | -1.5% | +1.0% | -7.6% | +1.6% | +1.1% |
| Jan 19 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $3.33 | $3.28 | -1.4% | -8.3% | +0.3% | +10.5% | -1.2% | -3.3% |
| May 24 | Goldman Sachs | Maintains | Sell → Sell | — | $3.69 | $3.59 | -2.7% | -1.9% | -4.1% | +8.6% | +5.6% | -9.0% |
| May 18 | Baird | Upgrade | Neutral → Outperform | — | $3.48 | $3.56 | +2.3% | -6.0% | +20.2% | -3.8% | -2.4% | -1.9% |
| May 13 | Barclays | Maintains | Overweight → Overweight | — | $3.05 | $2.93 | -3.9% | +3.9% | -0.9% | +10.8% | -6.0% | +20.2% |
| Jan 6 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $7.80 | $7.54 | -3.3% | +1.5% | -2.5% | +2.6% | +1.1% | -3.1% |
| Nov 30 | JMP Securities | Maintains | Market Outperform → Outperform | — | $8.37 | $8.75 | +4.5% | +3.0% | +2.1% | -2.2% | -4.3% | -2.3% |
| Oct 8 | Baird | Downgrade | Outperform → Neutral | — | $12.02 | $10.11 | -15.9% | -24.2% | -0.9% | +1.3% | +5.1% | +11.2% |
| Apr 28 | Guggenheim | Downgrade | Buy → Neutral | — | $20.01 | $19.49 | -2.6% | -5.7% | +0.3% | -1.6% | -2.4% | -6.4% |
| Mar 16 | Baird | Upgrade | Neutral → Outperform | — | $21.76 | $22.90 | +5.2% | +0.9% | -3.3% | -6.7% | +8.2% | +1.1% |
| Oct 15 | Baird | Downgrade | Outperform → Neutral | — | $21.92 | $20.28 | -7.5% | -11.9% | +1.9% | -5.7% | -2.6% | -5.5% |
| Aug 19 | Citigroup | Upgrade | Neutral → Buy | — | $17.96 | $19.36 | +7.8% | +6.3% | -3.0% | -1.2% | +0.3% | +0.1% |
| Jul 7 | Baird | Maintains | Outperform → Outperform | — | $19.05 | $16.15 | -15.2% | -14.3% | +8.1% | -1.5% | -2.7% | -2.4% |
| Mar 6 | Goldman Sachs | Downgrade | Neutral → Sell | — | $15.74 | $14.67 | -6.8% | -7.0% | -17.3% | +2.6% | -8.0% | -12.9% |
| Feb 19 | BTIG Research | Maintains | Buy → Buy | — | $17.03 | $17.47 | +2.6% | +9.2% | +1.0% | +0.3% | -9.5% | -4.1% |
| Feb 19 | BTIG | Maintains | Buy → Buy | — | $17.03 | $17.47 | +2.6% | +9.2% | +1.0% | +0.3% | -9.5% | -4.1% |
| Aug 9 | BTIG | Maintains | Buy → Buy | — | $13.86 | $14.12 | +1.9% | -3.7% | -1.0% | -0.1% | -7.6% | -3.8% |
| Mar 14 | William Blair | Maintains | Outperform → Outperform | — | $18.87 | $18.94 | +0.4% | +0.8% | +1.5% | +2.3% | -2.1% | -1.3% |
| Dec 19 | Goldman Sachs | Maintains | Neutral → Neutral | — | $17.75 | $18.42 | +3.8% | -2.3% | -5.7% | -4.8% | +0.6% | +3.1% |
| Jul 16 | Barclays | Maintains | Overweight → Overweight | — | $28.35 | $30.49 | +7.5% | +4.0% | +1.7% | +2.0% | -1.7% | -0.2% |
| Jun 12 | Oppenheimer | Maintains | Outperform → Outperform | — | $30.21 | $30.54 | +1.1% | +1.8% | -0.0% | +1.3% | -2.1% | -3.0% |
| Mar 16 | Guggenheim | Maintains | Neutral → Neutral | — | $35.09 | $34.42 | -1.9% | -4.1% | -2.3% | +1.9% | -2.1% | -2.0% |
| Sep 6 | Nomura | Maintains | Buy → Buy | — | $25.66 | $25.89 | +0.9% | -2.7% | +2.2% | +6.1% | +1.1% | -1.2% |
| Mar 2 | Nomura | Maintains | Buy → Buy | — | $22.89 | $21.71 | -5.2% | -5.3% | +3.1% | -0.4% | -3.7% | +5.7% |
| Apr 5 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $28.05 | $27.84 | -0.7% | +3.9% | +6.3% | -5.2% | -1.8% | -2.7% |
| Jul 20 | BofA Securities | Maintains | Buy → Buy | — | $39.78 | $41.13 | +3.4% | -3.1% | -3.3% | -0.4% | -1.6% | -2.5% |
| May 22 | Oppenheimer | Maintains | Outperform → Outperform | — | $30.80 | $32.38 | +5.1% | +10.4% | +7.2% | +12.5% | +16.3% | -10.0% |
| Apr 20 | Piper Sandler | Maintains | Overweight → Overweight | — | $32.59 | $34.15 | +4.8% | -0.3% | -0.9% | -2.8% | +4.4% | -0.2% |
| Apr 20 | Jefferies | Maintains | Buy → Buy | — | $32.59 | $34.15 | +4.8% | -0.3% | -0.9% | -2.8% | +4.4% | -0.2% |
No insider trades available.
No recent filings available.
Institutional (13F) — Top 15
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 174,352 | $844K | Reduced | Dec 2025 |
| 2 | Eversource Wealth Advisors, Llc | 5,092 | $525K | Added | Mar 2026 |
| 3 | Susquehanna International Group, Llp | 65,942 | $209K | Added | Mar 2026 |
| 4 | Citadel Advisors Llc | 44,315 | $140K | Reduced | Mar 2026 |
| 5 | Marshall Wace, Llp | 41,112 | $130K | Reduced | Mar 2026 |
| 6 | Bnp Paribas Financial Markets | 41,000 | $130K | Reduced | Mar 2026 |
| 7 | Ubs Group Ag | 29,774 | $94K | Reduced | Mar 2026 |
| 8 | Delaney Dennis R | 24,000 | $76K | — | Mar 2026 |
| 9 | Quadrant Capital Group Llc | 1,888 | $52K | Reduced | Mar 2026 |
| 10 | First Affirmative Financial Network | 10,149 | $29K | — | Mar 2026 |
| 11 | Citigroup Inc | 2,558 | $12K | Added | Dec 2025 |
| 12 | Wells Fargo & Company/mn | 3,150 | $10K | New | Mar 2026 |
| 13 | Atlantic Union Bankshares Corp | 1,500 | $7K | — | Dec 2025 |
| 14 | Gamma Investing Llc | 734 | $2K | Reduced | Mar 2026 |
| 15 | Barclays Plc | 224 | $710 | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 1
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | iShares Biotechnology ETF | 339,873 | $1M | Mar 2026 |
Valuation
Market Cap
$293.2M
Enterprise Value
$148.1M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.11x
P/B
3.86x
P/S
4.30x
P/FCF
-6.65x
EV/EBITDA
—
Shares Out
100.3M
Financials (TTM)
Revenue
$68.1M
Net Income
-$67.3M
EBITDA
-$51.1M
Free Cash Flow
-$42.5M
Op Cash Flow
-$40.1M
EPS Basic
$-0.68
EPS Diluted
$-0.68
EPS Forward
$-1.09
Gross Margin
81.9%
Op Margin
-67.5%
Net Margin
-98.8%
Balance Sheet
Total Assets
$324.7M
Total Liab.
$248.8M
Total Equity
$75.9M
Cash
$208.7M
LT Debt
$74.0M
Book Value/Sh
$0.76
Debt/Equity
1.58x
Current Ratio
1.62
Quick Ratio
1.62
Returns & Growth
ROE
—
ROA
—
ROIC
-18.6%
Rev Growth YoY
+76.3%
EPS Growth YoY
-65.8%
Price Returns
2W
-13.5%
1M
-9.7%
3M
-9.3%
6M
-30.6%
12M
+141.1%
Technicals
52W High
$5.48
52W Low
$1.40
50d MA
$3.65
200d MA
$3.81
RSI (14)
26.10
ATR (14)
$0.16
Beta
2.71
Avg Volume
46K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$6.00
High
$8.00
Low
$4.00
Median
$6.00
Data updated apr 26, 2026 10:10am
· Source: financialmodelingprep.com